Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III trial evaluating the role of adjuvant pegylated liposomal doxorubicin (PLD, Caelyx, Doxil) for women (age 66 years or older) with endocrine nonresponsive breast cancer who are not suitable for being offered a 'standard chemotherapy regimen'

X
Trial Profile

Phase III trial evaluating the role of adjuvant pegylated liposomal doxorubicin (PLD, Caelyx, Doxil) for women (age 66 years or older) with endocrine nonresponsive breast cancer who are not suitable for being offered a 'standard chemotherapy regimen'

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 19 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Doxorubicin liposomal (Primary) ; Cyclophosphamide; Methotrexate
  • Indications Ductal carcinoma; Early breast cancer; Menopause
  • Focus Therapeutic Use
  • Acronyms CASA
  • Most Recent Events

    • 14 Oct 2021 This trial has been completed in France (End Date: 31 Dec 2011), according to European Clinical Trials Database record.
    • 20 Jul 2012 Additional lead trial investigators identified as reported by ClinicalTrials.gov.
    • 20 Jul 2012 Actual end date (1 Dec 2011) added as reported by ClinicalTrials.gov.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top